| abstract |
Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula:The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes. |